Tennessee-based Graceway Pharmaceuticals, a portfolio company of GTCR Golder Rauner, has acquired worldwide rights to a Gilead Sciences molecule. Financial details of the deal were not disclosed. Graceway gains the topical drug GS 9191, which Gilead studied for external genital warts in a recent Phase II study. Graceway is hoping that GS 9191 will be effective in other skin conditions characterized by excessive cellular proliferation.
"The transaction with Gilead today is similar to our previous transaction with Pfizer in that we have licensed important compounds, processes, and intellectual properties that we hope will lead to exciting products for the treatment of important dermatological conditions faced by patients," stated Jefferson J. Gregory, Chairman and CEO of Graceway.
- check out Graceway's release